Polycomb segment myeloid malignancies.
暂无分享,去创建一个
[1] T. Haferlach,et al. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. , 2012, Blood.
[2] A. Jankowska,et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors , 2011, Leukemia.
[3] K. Döhner,et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. , 2012, Blood.
[4] A. Jankowska,et al. Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS , 2011 .
[5] P. Guglielmelli,et al. EZH2 mutational status predicts poor survival in myelofibrosis. , 2011, Blood.
[6] J. Maciejewski,et al. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.
[7] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[8] Reinhold Munker,et al. RUNX1 regulates corepressor interactions of PU.1. , 2011, Blood.
[9] P. Vyas,et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.
[10] A. Jankowska,et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.
[11] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[12] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[13] Heidi Dvinge,et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. , 2008, Cancer cell.
[14] Laurie E Ailles,et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.